FierceBiotech's 2015 Fierce 15
Whatever lies ahead for biotech in 2016, we can now look back on a 3-year-long stretch of good times for the industry. Venture groups have used the wave of biotech IPO exits and M&A deals to go back and raise more money from institutional investors. And as billions of dollars in fresh capital has converged with brilliant new scientific thinking, the result is a whole new wave of standout innovators as represented here by the Fierce 15.
Printed from https://innovationblog.partners.org/fiercebiotechs-2015-fierce-15 · Published 06 Nov 2018
© PARTNERS HEALTHCARE. ALL RIGHTS RESERVED